The U.S. Drug Enforcement Administration (DEA) has extended the temporary telemedicine flexibilities allowing providers to prescribe controlled substances without an initial in-person visit through December 31, 2025, previously set to expire at the end of 2024.
These flexibilities were initially introduced during the COVID-19 public health emergency to ensure continued access to critical healthcare services. They have since played a key role in expanding access to care, and in 2023, the DEA’s proposed permanent telemedicine rules drew over 38,000 public comments. The DEA elected to not reopen the public comment period, instead stating that it will use the extension to evaluate the already received input and finalize a set of telemedicine regulations. Learn more here.
Last Updated on November 22, 2024 by Aimed Alliance
